礼来公司 （Eli Lilly） 的盈利超出预期，上调了 2025 年的指引，其股价接近 821 美元。 Eli Lilly beat earnings estimates, raised 2025 guidance, and saw its stock trade near $821.

Elilly报告第二季度成绩强劲,Elili报称,EPS6.31美元,年收入增长37.6%,增至155.6亿美元,超过了估计数。 Eli Lilly reported strong second-quarter results, with $6.31 EPS and a 37.6% year-over-year revenue increase to $15.56 billion, surpassing estimates. 该公司将其2025年EPS指导提高到21.75-23.00美元,市场上限为776.75亿美元。 The company raised its 2025 EPS guidance to $21.75–23.00 and has a market cap of $776.75 billion. 机构所有权占82.5%,Mirae资产公司和Ameritas公司减少了股权。 Institutional ownership stands at 82.5%, with Mirae Asset and Ameritas reducing stakes. 分析师有好坏参半的评级,导致达成“机动购买”共识和939.61美元的平均价格目标。 Analysts have mixed ratings, leading to a "Moderate Buy" consensus and a $939.61 average price target. 该股票以820.69美元开业,以53.64美元的P/E交易。 The stock opened at $820.69, trading at a P/E of 53.64.